Dain Rauscher Wessels Initiates Coverage of Genomics, Life Science and Drug Discovery Companies.Business Editors NOTE TO EDITORS: The following is an investment opinion issued by Dain Rauscher Wessels MINNEAPOLIS--(BUSINESS WIRE)--Sept. 6, 2000 Dain Rauscher Wessels analyst Todd Nelson Todd Nelson is the chief weather anchor for fox 21 news at 9 out of Duluth, MN. before he became a member of the fox 21 team, he was the morning weather anchor for the Northlands NewsCenter (also out of Duluth. today introduced research coverage on the genomics, and life science and drug discovery technology sector. He initiated coverage of the following companies: Genomics-Driven Biopharmaceuticals -- Human Genome Sciences Human Genome Sciences NASDAQ: HGSI is a biopharmaceutical corporation founded in 1992. Its stated purpose is to "discover, develop, manufacture and market innovative drugs that serve patients with unmet medical needs, with a primary focus on protein and antibody drugs. Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : HGSI HGSI Human Genome Sciences, Inc. (Rockville, MD) ), $166.06, with a Buy-Aggressive Risk rating. Nelson's 12-month price target is $210. Drug Target Discovery Companies -- CuraGen Corp. (NASDAQ: CRGN), $43.88, with a Buy-Aggressive Risk rating. The 12-month price target is $59. -- Genencor International Inc. (NASDAQ: GCOR), $34.63, with a Strong Buy-Aggressive Risk rating. Nelson's six-month price target is $52. -- Myriad Genetics Inc. (NASDAQ: MYGN), $144.81, with a Strong Buy-Aggressive Risk rating. The six-month price target is $225. Information Companies -- Celera Genomics Group (NYSE NYSE See: New York Stock Exchange : CRA See Community Reinvestment Act. ), $104.50, with a Buy-Aggressive Risk rating. The 12-month price target is $151. -- Gene Logic Inc. (NASDAQ: GLGC), $25.19, with a Buy-Speculative Risk rating. Nelson's 12-month price target is $40. -- Incyte Genomics Inc. (NASDAQ: INCY), $38.56, with a Buy-Aggressive Risk rating. The 12-month price target is $63. Life Science and Drug Discovery Technology Companies -- Affymetrix Inc. (NASDAQ: AFFX), $74.94, with a Buy-Aggressive Risk rating. The 12-month price target is $112. -- Nanogen Inc. (NASDAQ: NGEN NGEN Next Generation NGEN Next Generation Enterprise Network (US Navy Intranet Development Program) ), $23.63, with a Buy-Speculative Risk rating. The 12-month price target is $35. -- PE Biosystems Group (NYSE: PEB PEB Physical Evaluation Board PEB Presidential Emergency Board PEB Post Exposure Bake PEB Professional Engineers Board (Singapore) PEB Pre-Engineered Building PEB Personal Electronic Ballot PEB Performance Evaluation Board ), $94.06, with a Buy-Average Risk rating. The 12-month price target is $136. -- Techne Corp. (NASDAQ: TECH), $97.00, with a Buy-Average Risk rating. The 12-month price target is $128. In addition, Nelson assumed coverage of Genomic Solutions Inc. (NASDAQ: GNSL), $18.00, which has a Strong-Buy-Aggressive Risk rating. Institutional investors interested in receiving more information should contact their Dain Rauscher Wessels salesperson. Media interested in receiving Nelson's reports should call 612-371-7752. The Dain Rauscher Wessels division includes equity research, equity trading In finance, equity trading is the buying and selling of company stock shares. Shares in large publicly-traded companies are bought and sold through one of the major stock exchanges, such as the New York Stock Exchange, London Stock Exchange or Tokyo Stock Exchange, which serve as , institutional equity sales and corporate finance. The division's 38 analysts focus on five industries: consumer, energy, financial services, health care and technology. Currently, the analysts follow more than 400 companies. The division, which employs more than 425 people, has offices in Austin, Texas; Boston; Chicago; Dallas; Houston; Minneapolis; Menlo Park, Calif.; New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. ; Paris; San Francisco; Seattle; and Tel Aviv, Israel.(a) Minneapolis-based Dain Rauscher Incorporated provides investment services to individual investors and small businesses through offices in 26 predominantly western states, investment banking services to corporations and municipalities nationwide, and trade clearing and settlement services to nonaffiliated broker-dealers throughout the United States and abroad. Dain Rauscher Incorporated, one of the nation's largest full-service securities firms, is a member of the New York Stock Exchange New York Stock Exchange (NYSE) World's largest marketplace for securities. The exchange began as an informal meeting of 24 men in 1792 on what is now Wall Street in New York City. and other major securities exchanges, as well as the Securities Investor Protection Corp. Dain Rauscher Corporation, its holding company, trades on the New York Stock Exchange under the symbol DRC DRC Democratic Republic of Congo DRC Down (Stage) Right Center DRC Director(ate) of Reserve Components DRC Disability Rights Commission (United Kingdom) . The firm's headquarters are located at Dain Rauscher Plaza, 60 S. Sixth St. Dain Rauscher Inc. managed or co-managed a public offering of the securities of CuraGen, Gene Logic, Nanogen and Genomic Solutions within the past three years. Dain Rauscher Inc makes a market in Affymetrix, CuraGen, Human Genome Sciences, Myriad Genetics, Techne, Gene Logic, Nanogen, Genomic Solutions, Incyte Genomics, Genencor International and may act as principal with regard to sales or purchases of these securities. Additional information on the securities mentioned is available on request. This does not purport to be a complete statement of all material facts related to any company, industry, or security mentioned. The information provided, while not guaranteed as to accuracy or completeness, has been obtained from sources believed to be reliable. The opinions expressed reflect our judgment at this time and are subject to change without notice and may or may not be updated. DRI See Digital Research. , its officers, directors, affiliates, and/or employees (including the authors of this report) may from time to time have a long or short position in publicly or privately issued securities of companies mentioned or derivatives thereof and may sell or buy such securities for their own or related accounts. This notice shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which said offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state. (a) Strategic alliance with Tamir Fishman & Co |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion